<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00338442</url>
  </required_header>
  <id_info>
    <org_study_id>VZ-009</org_study_id>
    <nct_id>NCT00338442</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection</brief_title>
  <official_title>Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cangene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cangene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess VariZIG™ for the treatment of patients at risk for developing serious&#xD;
      complications from chicken pox.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In most individuals, chicken pox or varicella zoster (VZV) infections are benign; however, in&#xD;
      certain at-risk populations such as immunocompromised patients or infants VZV disease can&#xD;
      produce significant morbidity and mortality. In such patients, varicella zoster immune&#xD;
      globulin (VZIG) has been used to prevent or reduce the severity of VZV infections in at-risk&#xD;
      patients exposed to individuals with active infections. Massachusetts Public Health Biologic&#xD;
      Laboratories (Boston, MA) has discontinued manufacture of the only FDA approved VZIG product.&#xD;
      Cangene Corporation (Winnipeg, Canada) is conducting this expanded access IND protocol for&#xD;
      VariZIG™, which is a purified human immune globulin preparation made from plasma of donors&#xD;
      with high anti-varicella antibody titers.&#xD;
&#xD;
      This study is an open label, non-randomized, expanded access study that will make VariZIG™&#xD;
      available to eligible patients for whom there is no alternative licensed treatment while a&#xD;
      pivotal study is conducted. The study will begin recruiting in February 2006 and will collect&#xD;
      safety and basic efficacy data over 42 days following VariZIG™ administration. Physicians&#xD;
      will be required to assess measures of varicella infection as well as provide study specific&#xD;
      documentation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <study_type>Expanded Access</study_type>
  <condition>Varicella</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VariZIG™</intervention_name>
    <description>Biological / Vaccine</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Cangene Corporation VariZIG™ release requirement.&#xD;
&#xD;
          -  Any of the following at-risk patients exposed to varicella within the previous 96&#xD;
             hours:&#xD;
&#xD;
               -  Immunocompromised pediatric or adult patients.&#xD;
&#xD;
               -  Neonates (less than 1 year of age) and pre-term infants.&#xD;
&#xD;
               -  Pregnant women.&#xD;
&#xD;
               -  Newborns whose mothers had VZV infection shortly before delivery (&lt; 5 days) or&#xD;
                  after (&lt; 2 days) delivery.&#xD;
&#xD;
               -  Healthy non-immune adults&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to blood or blood products, including intravenous (IV) or&#xD;
             intramuscular (IM) human immunoglobulin preparations.&#xD;
&#xD;
          -  Selective immunoglobulin A (IgA) deficiency.&#xD;
&#xD;
          -  Evidence of VZV infection.&#xD;
&#xD;
          -  Evidence of zoster infection.&#xD;
&#xD;
          -  Known immunity to VZV(previous varicella infection or varicella vaccination)&#xD;
&#xD;
          -  Severely thrombocytopenic ( platelets &lt; 50 x 10x9 / L )&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Gale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FFF Enterprises</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>June 15, 2006</study_first_submitted>
  <study_first_submitted_qc>June 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <last_update_submitted>April 1, 2013</last_update_submitted>
  <last_update_submitted_qc>April 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune compromised</keyword>
  <keyword>Varicella Zoster Virus ( VZV) Infection</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

